Shares of C R Bard Inc (NYSE:BCR) have earned an average recommendation of “Hold” from the eleven research firms that are covering the company, MarketBeat reports. One research analyst has rated the stock with a sell rating, eight have given a hold rating and one has given a buy rating to the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $332.00.
Several research firms have commented on BCR. Zacks Investment Research upgraded shares of C R Bard from a “hold” rating to a “buy” rating and set a $372.00 price target for the company in a report on Tuesday, December 26th. ValuEngine cut shares of C R Bard from a “buy” rating to a “hold” rating in a report on Friday, December 1st. Barclays boosted their price target on shares of C R Bard from $245.00 to $337.00 and gave the stock an “equal weight” rating in a report on Monday, November 6th. Cowen reiterated a “hold” rating and set a $317.00 price target on shares of C R Bard in a report on Friday, November 3rd. Finally, Needham & Company LLC reiterated a “hold” rating on shares of C R Bard in a report on Thursday, October 26th.
In other news, insider Jim C. Beasley sold 3,395 shares of the company’s stock in a transaction on Thursday, December 14th. The shares were sold at an average price of $332.00, for a total value of $1,127,140.00. Following the completion of the transaction, the insider now owns 25,630 shares in the company, valued at approximately $8,509,160. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, VP John A. Deford sold 14,107 shares of the company’s stock in a transaction on Wednesday, December 20th. The shares were sold at an average price of $333.48, for a total transaction of $4,704,402.36. The disclosure for this sale can be found here. Insiders have sold a total of 32,546 shares of company stock valued at $10,826,150 in the last quarter. 0.80% of the stock is currently owned by company insiders.
Several institutional investors have recently modified their holdings of BCR. HighTower Advisors LLC boosted its holdings in shares of C R Bard by 15.3% in the 2nd quarter. HighTower Advisors LLC now owns 2,698 shares of the medical instruments supplier’s stock valued at $854,000 after buying an additional 358 shares in the last quarter. WINTON GROUP Ltd acquired a new position in shares of C R Bard in the 2nd quarter valued at $3,947,000. Toronto Dominion Bank boosted its holdings in shares of C R Bard by 26.1% in the 2nd quarter. Toronto Dominion Bank now owns 24,528 shares of the medical instruments supplier’s stock valued at $7,752,000 after buying an additional 5,077 shares in the last quarter. Paulson & CO. Inc. acquired a new position in shares of C R Bard in the 2nd quarter valued at $13,315,000. Finally, Yorkville Capital Management LLC acquired a new position in shares of C R Bard in the 2nd quarter valued at $1,043,000. Institutional investors and hedge funds own 79.11% of the company’s stock.
Shares of C R Bard (NYSE BCR) remained flat at $$331.24 on Friday. C R Bard has a fifty-two week low of $223.02 and a fifty-two week high of $337.73. The company has a market cap of $24,140.00, a P/E ratio of 43.64, a price-to-earnings-growth ratio of 2.53 and a beta of 0.52. The company has a current ratio of 1.72, a quick ratio of 1.37 and a debt-to-equity ratio of 0.57.
COPYRIGHT VIOLATION WARNING: “C R Bard Inc (BCR) Receives $332.00 Average Price Target from Analysts” was originally published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this story on another domain, it was stolen and republished in violation of United States & international copyright & trademark laws. The correct version of this story can be accessed at https://ledgergazette.com/2018/02/18/c-r-bard-inc-bcr-receives-332-00-average-price-target-from-analysts.html.
C R Bard Company Profile
C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.
Receive News & Ratings for C R Bard Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C R Bard and related companies with MarketBeat.com's FREE daily email newsletter.